<SEC-DOCUMENT>0000939767-24-000116.txt : 20240806
<SEC-HEADER>0000939767-24-000116.hdr.sgml : 20240806
<ACCEPTANCE-DATETIME>20240806160846
ACCESSION NUMBER:		0000939767-24-000116
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240806
DATE AS OF CHANGE:		20240806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		241179248

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20240806.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09cb6ac2-199a-4658-92e7-be7edaf58e8a,g:cfcb6897-bae4-462e-852c-f27a52e7413c,d:34b1ba34666248dcb1f9448928952316-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20240806</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-21">8/6/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20240806.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-06</xbrli:startDate><xbrli:endDate>2024-08-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i34b1ba34666248dcb1f9448928952316_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 06, 2024</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20240806_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $0.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i34b1ba34666248dcb1f9448928952316_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended June&#160;28, 2024, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01.  Other Events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2024, Exelixis announced that the Board of Directors authorized the repurchase of up to $500 million of its common stock before the end of 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled &#8220;Announcement of Additional Stock Repurchase Program for up to $500 Million through the End of 2025.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20240630exhibit991.htm">Press Release issued August 6, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i34b1ba34666248dcb1f9448928952316_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel <br/>and Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20240630exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i81a1f947daf74b85bcf7443330b61352_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:9pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">EVP, Public Affairs &#38; Investor Relations</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-8194</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application (sNDA) for Cabozantinib in Advanced Neuroendocrine Tumors (NET) - </font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Earned $150 million Cabozantinib Sales-Based Milestone from Ipsen -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Completed $450 million Stock Repurchase Program for 2024 - </font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Announced Additional Stock Repurchase Program for up to $500 million through the End of 2025 - </font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM Eastern Time -</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ALAMEDA, Calif. &#8211; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">August&#160;6, 2024 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the second quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exelixis is well positioned for an impactful second half of 2024 as we continue to grow the cabozantinib franchise, execute on our regulatory and development objectives, and advance our next-generation pipeline,&#8221; said Michael M. Morrissey, Ph.D., President and CEO, Exelixis. &#8220;Cabozantinib&#8217;s second quarter commercial performance was strong both in the U.S. and globally, with Ipsen&#8217;s success prompting a $150 million milestone payment to Exelixis based on sales over the past four quarters. On the regulatory front, the FDA accepted the sNDA for cabozantinib in advanced NET, granted standard review and assigned a target action date of April 3, 2025. We&#8217;re actively preparing for launch and excited at the prospect of bringing this new treatment option to previously treated advanced NET patients with high unmet medical need. At the same time, we are prioritizing our clinical pipeline with plans to initiate a new phase 3 pivotal trial for zanzalintinib in NET, advance phase 1 efforts for XL309 and XB010, and discontinue development of XB002. I&#8217;d like to thank the entire Exelixis team for their hard work and contributions toward achieving these important milestones for cabozantinib and advancing our broad, differentiated pipeline of oncology therapeutics to help the patients we serve.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 2 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Second Quarter 2024 Financial Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were $637.2&#160;million, as compared to $469.8&#160;million for the comparable period in 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter ended June&#160;30, 2024 included net product revenues of $437.6 million, as compared to $409.6&#160;million for the comparable period in 2023. The increase in net product revenues was primarily due to an increase in sales volume and average net selling price.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $199.6&#160;million for the quarter ended June&#160;30, 2024, as compared to $60.2&#160;million for the comparable period in 2023. The increase in collaboration revenues was primarily related to an increase in milestone-related revenues recognized in the quarter and higher royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis&#8217; collaboration partners, Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited, partially offset by a decrease in development cost reimbursements earned. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2024 were $211.1&#160;million, as compared to $232.6&#160;million for the comparable period in 2023. The decrease in research and development expenses was primarily related to decreases in license and other collaboration costs and clinical trial costs, partially offset by an increase in manufacturing costs to support our development candidates.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2024 were $132.0&#160;million, as compared to $141.7 million for the comparable period in 2023. The decrease in selling, general and administrative expenses was primarily related to a decrease in legal and advisory fees related to the proxy contest in the prior year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for income taxes </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2024 was $66.7 million, as compared to $19.2&#160;million for the comparable period in 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2024 was $226.1&#160;million, or $0.78 per share, basic and $0.77 per share, diluted, as compared to GAAP net income of $81.2&#160;million, or $0.25 per share, basic and diluted, for the comparable period in 2023. GAAP net income per share for the quarter ended June&#160;30, 2024 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended June&#160;30, 2024, as compared to the comparable period in 2023, as a result of the stock repurchase programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2024 was $245.6&#160;million, or $0.85&#160;per share, basic and $0.84 per share, diluted, as compared to non-GAAP net income of $100.3&#160;million, or $0.31&#160;per share, basic and diluted, for the comparable period in 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation expense, adjusted for the related income tax effect for all periods presented. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 3 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation expense, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2024 Financial Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is providing the following updated financial guidance for fiscal year 2024 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:56.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.975 billion - $2.075 billion</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.650 billion - $1.750 billion</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$450 million - $500 million</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20% - 22%</font></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 financial guidance excludes expenses related to the restructuring plan announced in January 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $40 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $60 million of non-cash stock-based compensation expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cabozantinib and Pipeline Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Franchise Net Product Revenues and Royalties. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net product revenues generated by the cabozantinib franchise in the U.S. were $437.6&#160;million during the second quarter of 2024, with net product revenues of $433.3&#160;million from CABOMETYX&#174; (cabozantinib) and $4.2&#160;million from COMETRIQ&#174; (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners during the quarter ended June&#160;30, 2024, Exelixis earned $41.2&#160;million in royalty revenues. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Achievement of Cabozantinib Sales-Based Milestone from Ipsen. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today, Exelixis announced it earned and recognized in license revenues a $150 million commercial milestone from Ipsen during the second quarter of 2024 based on Ipsen achieving $600 million in cumulative net sales of cabozantinib in its related license territory over four consecutive quarters. Exelixis expects to receive the milestone payment during the third quarter of 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FDA Accepts for Standard Review the sNDA for Cabozantinib for Patients with Advanced NET&#59; Updated Results from Phase 3 CABINET Study to be Presented during an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today, Exelixis announced that the FDA accepted its sNDA for cabozantinib for patients with previously treated advanced pancreatic NET (pNET), and for patients with previously treated advanced extra-pancreatic NET (epNET). The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. The FDA also granted orphan drug designation to cabozantinib for the treatment of pNET. The application was based on results from the phase 3 CABINET trial, which </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 4 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">evaluated cabozantinib compared with placebo in patients with previously treated pNET and epNET. The CABINET study is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the NCI-funded Alliance for Clinical Trials in Oncology. Updated results from CABINET, including final results on the primary efficacy endpoint of progression-free survival by Blinded Independent Central Review, will be presented during the ESMO Congress 2024 in September.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Partner Ipsen Opts into Phase 3 CABINET Pivotal Trial in Advanced NET.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In July, Ipsen announced it opted into the phase 3 CABINET pivotal trial, expanding the existing collaboration and license agreement with Exelixis and permitting Ipsen to seek potential marketing authorizations for CABOMETYX in advanced pNET and epNET from regulatory authorities outside of the U.S. and Japan. As part of the agreement, Exelixis is eligible to receive a reimbursement of a portion of costs related to the trial, as well as milestone payments for potential future regulatory action by the European Medicines Agency. The decision to expand the existing agreement was based on detailed results from the CABINET trial, which were first presented at the ESMO Congress 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 3 CONTACT-02 Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study Update and Intention to Submit sNDA in 2024.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Today, Exelixis announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed. This study is evaluating cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with mCRPC and measurable soft-tissue disease who have progressed after treatment with one prior NHT. As previously reported, the CONTACT-02 study met one of its two primary endpoints, demonstrating a statistically significant benefit in progression-free survival (PFS) (hazard ratio&#58; 0.65&#59; 95% confidence interval&#58; 0.50&#8211;0.84&#59; p&#61;0.0007) in the predefined PFS intent-to-treat population (i.e., the first 400 randomized patients). While final OS continued to favor the combination of cabozantinib and atezolizumab, it did not achieve statistical significance. The safety profile of the combination regimen was reflective of the known safety profiles for each single agent and was consistent with the known tolerability profile of approved immune checkpoint inhibitor-tyrosine kinase inhibitor combinations in advanced solid tumors. Exelixis intends to submit an sNDA to the FDA this year and to present these final data at a future medical meeting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enrollment Completion for Zanzalintinib Phase 3 STELLAR-303 Study and Announcement of New Pivotal Trial for Zanzalintinib in Neuroendocrine Tumors. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today, Exelixis announced that enrollment has been completed in the STELLAR-303 phase 3 pivotal study. STELLAR-303 is evaluating zanzalintinib in combination with atezolizumab compared with regorafenib in patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient. The primary endpoint in the study is OS in the patients without liver metastases. Exelixis anticipates preliminary results from the study to readout in 2025. Additionally, Exelixis intends to initiate a new phase 3 pivotal trial, STELLAR-311, evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with pNET and epNET, in the first half of 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Today, Exelixis announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally advanced or metastatic solid tumors. XB010, an antibody-drug conjugate (ADC) consisting of a monomethyl auristatin E payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4, is the first custom ADC generated through Exelixis&#8217; biotherapeutics collaboration network. The dose-escalation stage of this phase 1, global, open-label study will evaluate XB010 as a single agent and in combination with pembrolizumab to inform the cohort-expansion stage. The expansion cohorts are designed to further assess the tolerability and activity of monotherapy and of the combination in specific indications. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Portfolio Prioritization Update. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis announced it will discontinue the development of XB002, the company&#8217;s tissue factor (TF)-targeting ADC, as part of its portfolio prioritization efforts. Based on available data, the compound is unlikely to improve upon tisotumab vedotin or other competitor TF-targeting ADCs currently in development. The company plans to disclose data from the phase 1 JEWEL-101 study, evaluating XB002 in </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 5 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">advanced solid tumors, at a later date. Preclinical development of XB371, its ADC consisting of a topoisomerase payload conjugated to a TF-targeting monoclonal antibody, is ongoing.  Exelixis plans to reallocate resources to new pivotal trials with zanzalintinib, advancing XL309 and its growing pipeline.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Settlement of CABOMETYX Patent Litigation with Cipla Limited and Cipla USA. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In May, Exelixis entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla) resolving two patent litigations brought by Exelixis in response to Cipla&#8217;s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX tablets (20 mg &#47; 40 mg &#47; 60 mg) prior to the expiration of the applicable patents. Pursuant to the terms of the Agreement, Exelixis will grant Cipla a license to market generic versions of CABOMETYX in the United States beginning on January 1, 2031, if approved by the FDA and subject to conditions and exceptions common to agreements of this type. The U.S. District Court for the District of Delaware dismissed the case without prejudice in July 2024 per the parties&#8217; joint request, effectively terminating all ongoing Hatch-Waxman litigation between Exelixis and Cipla regarding CABOMETYX patents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Completion of the $450 million 2024 Stock Repurchase Program. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, Exelixis completed the repurchase of 20.3 million shares of the company&#8217;s common stock for a total of $450 million, fulfilling its commitment under the stock repurchase program announced in January 2024. With the completion of this 2024 stock repurchase program, the company has returned $1 billion to shareholders since the initial $550 million stock repurchase program was authorized in March 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Announcement of Additional Stock Repurchase Program for up to $500 million through the End of 2025. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today, Exelixis announced that the company&#8217;s Board of Directors has authorized the repurchase of up to an additional $500 million of the company&#8217;s common stock through the end of 2025. The newly authorized stock repurchase program is the third such program undertaken by Exelixis since March 2023. Stock repurchases under the newly authorized program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any stock repurchases under the stock repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis&#8217; common stock and general market conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31. For convenience, references in this press release as of and for the fiscal periods ended June&#160;28, 2024 are indicated as being as of and for the periods ended</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June&#160;30, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the second quarter of 2024 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Tuesday, August&#160;6, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please register using this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will also be archived on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 6 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow &#64;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ExelixisInc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on LinkedIn. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; belief that it is well-positioned for an impactful second half of 2024&#59; the regulatory review process with respect to Exelixis&#8217; sNDA for cabozantinib in advanced NET, including the PDUFA target action date assigned by the FDA, and the potential to bring cabozantinib as a new treatment option for these patients with high unmet medical need&#59; Exelixis&#8217; plans to reallocate resources to new pivotal trials in zanzalintinib and to advancing phase 1 efforts for XL309 and XB010, as well as to the rest of the company&#8217;s growing pipeline&#59; Exelixis&#8217; updated 2024 financial guidance&#59; the anticipated timing for receipt of a $150 million milestone payment from Ipsen&#59; Exelixis&#8217; plans to present updated results from CABINET, including final results for the primary efficacy endpoint of PFS, at the ESMO Congress 2024 in September&#59; Exelixis&#8217; expectation to receive reimbursement payments from Ipsen relating to  CABINET, as well as milestone payments for potential future regulatory actions by the European Medicines Agency&#59; Exelixis&#8217; plans to submit an sNDA for the combination of cabozantinib and atezolizumab in mCRPC to the FDA this year based on the results of CONTACT-02, and to present final data from CONTACT-02 at a future medical meeting&#59; Exelixis&#8217; expectation that preliminary results from STELLAR-303 will readout in 2025&#59; Exelixis&#8217; plans to initiate STELLAR-311 in the first half of 2025&#59; Exelixis&#8217; plans to disclose data from JEWEL-101 at a later date&#59; Exelixis&#8217; future obligations under the Agreement settling the company&#8217;s patent litigation with Cipla&#59; Exelixis&#8217; plans to repurchase up to an additional $500 million of its common stock before the end of 2025&#59; and Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 7 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i81a1f947daf74b85bcf7443330b61352_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 8 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.660%"><tr><td style="width:1.0%"></td><td style="width:37.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">437,581&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">409,646&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">816,104&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">773,046&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">License revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">194,986&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,747&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">239,662&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">91,039&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration services revenues</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,611&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,455&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,638&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,551&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">637,178&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">469,848&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,062,404&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">878,636&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,667&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,705&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38,923&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,020&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211,147&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">232,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">438,836&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">466,816&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">132,015&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">141,723&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">245,999&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">273,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">475&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33,310&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">361,304&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">391,998&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">757,068&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">771,956&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275,874&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77,850&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">305,336&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">106,680&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,258&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,541&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37,152&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,043&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(287)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(376)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(59)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">292,845&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100,386&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342,112&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">148,664&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">66,729&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,208&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78,679&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,458&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:18pt;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">226,116&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">81,178&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263,433&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121,206&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.78&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.89&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.37&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.77&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.88&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">289,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,205&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">294,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,312&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293,974&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">327,305&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299,752&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">326,792&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i81a1f947daf74b85bcf7443330b61352_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 9 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">August&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:36.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">226,116&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">81,178&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263,433&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121,206&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - research and development expenses&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,589&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,070&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,841&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - selling, general and administrative expenses&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,176&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,311&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31,397&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,720&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,841)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,781)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10,289)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9,642)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">245,629&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100,297&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">297,611&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">153,125&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.89&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.77&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.88&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.37&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.85&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.31&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.84&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.99&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">289,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,205&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">294,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,312&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293,974&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">327,305&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299,752&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">326,792&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Non-cash stock-based compensation expense used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20240806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09cb6ac2-199a-4658-92e7-be7edaf58e8a,g:cfcb6897-bae4-462e-852c-f27a52e7413c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20240806" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20240806">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20240806_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20240806_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20240806_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09cb6ac2-199a-4658-92e7-be7edaf58e8a,g:cfcb6897-bae4-462e-852c-f27a52e7413c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c37a85dc-f095-44d5-a741-5445c95c1fe6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8dcbf859-50a6-4d69-a967-d37b6632a5c3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cc61cef0-fbfd-4fa2-85e0-ab46ed5b45b0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e7f2766c-4c1f-487b-bb6d-f52f330fb241_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_64e3437f-ce0a-471b-a045-9722eb6f3203_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f2c50e13-023b-4095-9f8f-f58a3b4c2f4b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a1a283a6-40ac-4de4-b2fa-999b8e7bda37_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8f395ab1-6508-4ed4-8f6e-27741596b0b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_17dc94fd-fc9a-4fd6-b342-9a7b6e4ca9ec_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8237d681-3239-4322-8dd1-01bb8cc3f872_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d983f81e-3202-4e21-b7c1-d7725d62a06f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0e713259-c3c8-4d5a-bc98-a080c44bb332_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_992446d4-31b3-4965-96e1-c1b1186df59d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a3c0c4ae-011f-48f1-ad30-bdfd214b6465_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4005b94f-456f-4c71-be20-d024ccfcdc5a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0dd5c9d9-0102-4a65-a868-6b4582fe4b20_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_59bd1a6f-2950-4c8d-9de3-d3a8c46f9f62_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_96f7a28f-c255-47f5-9cbc-e72b014bed71_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_995a3421-a63f-4976-851f-738a20f56ebf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fc3a0ec3-c35c-4450-b76b-c3eed1bbb236_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9d1edacb-ff4a-4e2b-8977-cac0a694bf32_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_433ef02a-89a1-4f42-a8e5-5a365954c6e7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1c9edfe7-a910-4448-9dc3-ab794a6b926b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20240806_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09cb6ac2-199a-4658-92e7-be7edaf58e8a,g:cfcb6897-bae4-462e-852c-f27a52e7413c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20240806.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8fec3117-ee31-4305-a9bd-d7b6d8c21215" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_AmendmentFlag_8fec3117-ee31-4305-a9bd-d7b6d8c21215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6e08f420-5298-450c-a8ed-e2b8bc15e2c7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_DocumentPeriodEndDate_6e08f420-5298-450c-a8ed-e2b8bc15e2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ba8bbdc1-dd9a-41c0-aa28-2c22e4f686fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityRegistrantName_ba8bbdc1-dd9a-41c0-aa28-2c22e4f686fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_16600f50-4ae8-49c5-b0f7-1b56df6e6789" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityCentralIndexKey_16600f50-4ae8-49c5-b0f7-1b56df6e6789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_21e5a898-0e93-4919-9280-67c1f7fa5ded" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityEmergingGrowthCompany_21e5a898-0e93-4919-9280-67c1f7fa5ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bda8ffb3-7d47-40ac-9d58-aef0b50fe742" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_Security12bTitle_bda8ffb3-7d47-40ac-9d58-aef0b50fe742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_63fb4b47-6168-4d74-ba64-cdd9742caf97" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_TradingSymbol_63fb4b47-6168-4d74-ba64-cdd9742caf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a6813a63-592f-4a87-b3f1-eab184bfe828" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_SecurityExchangeName_a6813a63-592f-4a87-b3f1-eab184bfe828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f4fddf9e-809c-4793-928c-97ddf429b90e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityFileNumber_f4fddf9e-809c-4793-928c-97ddf429b90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_03157333-57ff-4f51-b226-ddf3ad5da717" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_03157333-57ff-4f51-b226-ddf3ad5da717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_66e79adc-55a2-4f66-9acd-8fd09e5df791" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityTaxIdentificationNumber_66e79adc-55a2-4f66-9acd-8fd09e5df791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_86c81188-1ad2-4d31-b0a3-7e0b7feed61f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityAddressAddressLine1_86c81188-1ad2-4d31-b0a3-7e0b7feed61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a5877dbd-fee2-4ae8-9097-de266c4126c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityAddressCityOrTown_a5877dbd-fee2-4ae8-9097-de266c4126c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_89885ce5-ec06-4db2-ac4d-49e621b43674" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityAddressStateOrProvince_89885ce5-ec06-4db2-ac4d-49e621b43674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6b48af38-19de-4a45-abc2-6def18072f4e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_EntityAddressPostalZipCode_6b48af38-19de-4a45-abc2-6def18072f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9a074cc3-cae4-4bc6-a3cb-e47cdd65201b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_CityAreaCode_9a074cc3-cae4-4bc6-a3cb-e47cdd65201b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b10369dd-fd4d-44e6-b345-d5031fc5a1ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_LocalPhoneNumber_b10369dd-fd4d-44e6-b345-d5031fc5a1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_59d3e409-ca9b-40b9-87af-aaf3903d03da" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_WrittenCommunications_59d3e409-ca9b-40b9-87af-aaf3903d03da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_34a3f0eb-87b6-41b3-a70c-84f4998aec83" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_SolicitingMaterial_34a3f0eb-87b6-41b3-a70c-84f4998aec83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_de20ed90-b251-4682-ab04-3972320051d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_PreCommencementTenderOffer_de20ed90-b251-4682-ab04-3972320051d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5ae94726-dcc6-4077-9e2f-2976565b5264" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5ae94726-dcc6-4077-9e2f-2976565b5264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_865a4819-2247-4096-8ca3-fbcefa3e1e08" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f959386b-e138-4233-845a-cb46cfd6350d" xlink:to="loc_dei_DocumentType_865a4819-2247-4096-8ca3-fbcefa3e1e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20240806_g1.jpg
<TEXT>
begin 644 exel-20240806_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
M  $   &" @( !     $   NE         $@    !    2     '_V/_M  Q!
M9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1
M%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ + "@ P$B  (1 0,1 ?_=
M  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$!
M 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A
M$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$
MDU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%1
M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4
MHQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G
M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]5261]:>LW]%Z0_-QZVV7;V5L%D[
M 7NV[W[=KG;6_F[ERM/UT^N>16+<?IK+ZG3MLJQ<A[#!VNVOKM<WVN&U)3Z"
MDN6^K?7/K5U'J1IZGT\8N&VISG6FBZD[Y:*F,=D6.:_=^D^BQ4\WZX];Z+UO
M[%UFBA^'.X7T,L:YU+C#<FL/MNW.I_[48_T_]'_@?52GM4E1ZEUG Z=TQW4[
MK _'VAU1K(<;"[^991^;8Z[\S_TFL'ZI_6'ZQ==RK++Z<:GIU$BQ[&6%[K")
M9CU6/MV?HFG??;Z7_6_TOZ%*>L27"]3^N_7J^M9/3NG8E-HHL-5=9KLMM?L$
MV/VT6,_E.VMK^@AGZW?7H"?V1_[)Y7_I1*E6]\DL3J76.H]-^JW[4R*&#J#:
MJ3;1J*VVVNKJ>WZ3W;*K+?H>I_UW\]2^JG6,OK/21FYC:VVFVRN*@YK88[:W
M2Q]KO^DDIV4E4ZMG'IW2\O/#/4.+2^T5S&XL:7!N[\U8WU2Z_P!4ZY@YEF0V
MBN^BSTZ36UX9)8VP&UK[7N=[W?FO8ET4-Z>AMMKIJ?;8=M=;2][O -&YQ6-@
M?6FC,S&XSJ'4MM.VFQS@9/+6V,'\WN_K6*O@=?NRLM_3.K4UUB[=2=DB'_1=
M39N>_P#G?\&]G_HQ'P_JSB=/R?MMN0Y]>/+V!X:T-@'WVV?G^FW_ (M4SFRY
M90E@(]L2K+Q:2C_>XO\ N6\,&+%')'F ?<,;P\/JC+^[P_UOWW6S<RG"QG9%
MT[6P UHESG'VLJK;^=98[VL4L;[0:&')#1<1+VMX:3KZ8/YWI_0W_P"$6)@6
MOZYU0YKP1T_ ,8M9'TK2/YY_\ME?N_X+?7_PJIN^MO4'?7%O0ZZJ6X8M]%[W
M!QM,4G(<]K@]M;/?[/YNQ3XI^Y<Q\GRP_K?O3_[QKYL8Q 8S_.?-D_J7\N/_
M +]ZQ)<_]:OK77T&NNNNL7YEX<YC'.VL8QNANN=]+;N/L9_A5SK_ *W_ %WI
MK^UW=/:W&C<7.Q;FL#?WB_U2ZMO\NQ2TPOH22YSIOUHR.J]#?U"G%.,]C_2+
MW>^HF/YVA_Z+U*]WZ'U+/2KIM_G?T5-JU^E95^5ABV\#=);N @.C\X?2^B[]
M'N9^BLV>K3^AV)*?_]#KO\8G_B=/_ABG_JES71/KY^Q>F4]-^Q-O]$O/J&_9
M/J/??_-^C9MV^IM^FNE_QB$#ZNF?^Y%/_5+$^KGUXZ;TCH]'3[\>^VVDV%SZ
MQ66G?99<W;ZEU;_HV?N(]$=7H_JK]:'_ %A&4XXGV:O&+&ML%AL:]S]Y>P.]
M*GW5-;7N_P"-1_K3T3%ZQTM[;7LHNQP;<?*?H*W >[U'?]Q[&^V__MS^<KK5
M;HGUUZ?UKJ P,;'R*[#6ZW=8*]H:PL:9].VQW^%_=6#]=OK!;U'+'U<Z6/6!
ML%>0&'6VZ?;A-/T?3J=[\MW_ %NS]'3DI*>:P?M75;.G]&?E"G&]4MQ_4/LJ
M-ON>6:?I+'_S>(Q_^$M]%GI,N7KG3\#&Z=A586(S910W:P=_%SW'\ZRQ_OL?
M^>]</U?Z@/Q^@U6XLY'4J 7YC621<UWN>RAG[^-_VFV^^UG_  ]BUOJ/]:6]
M6QA@95@?GX[)%A,^M4/:V_\ XUGT,C_M[_"_HTH/*9/4_P!D?7+,ZEZ8N^SY
M-WZ,NV [VFG^<VV;?I_N+99_C0LL>VNKI8LM>X-96S(ESG..UK&-;C>YSEDG
MJ='2OKQE=0O:ZRNC)OW,KVEYWL=4W;ZCJV_2?^^NB_\ ',Z/_P!Q,K[J?_>A
M)3H_7O\ \2V9_6H_\_TH'^+S_P 3@_X^[_JDWUKS:\_ZC69U;75UY3,6YC7P
M'!K[L=[=^TN;^=^\L'ZL?7/IW1>E#!R*+[;!999NJ],MAYW-_G+:W?\ 125U
M>P^M7_B:ZI_X5M_ZDK!_Q9_T+J'_ (8;_P">ZT?*^LF)U_ZK=;LQ:K:6XU%C
M'^J&"2ZOU/;Z5EOT6E _Q9ZX/4"-1]I:)[3Z5:2NK:^MV#4RRK.8X-LM/IV-
M!@DM&ZNUG\JO;M=_UI4>I]<R\["HQK!Z8+0Z]YT;:02UEFG_ &G]F]__  G_
M !7Z2\^I_P!8^L.()_9N)^CW@Z.[O%?\N]WYS?\ M/Z?^D6A]8>D-RL%MF-6
M!=B#]&Q@YK'TZ&M;_)'Z)963%DR>_DQ'AQRTX?\ /</SR'\O6[./+CQ?=L6;
MU9(Z\1_R''_-Q/\ S?\ 9NAT[#JP<*K&J.YK!J_]YQ]S[/[;EP#?_P I?_H6
M?_;9=1]5.JMOH^P6.FRALT']ZK]W_K/T/^+]-<NT@_XS(&I^UG3OIBJ_R\X3
MQ1E#2-5P_NU^BYG-8YX\TXY-97?%^_Q?I.E]?_J_U#,R*>J853LEM=7HWU5B
M;&@.-E5U=?TK?=8_U/3_ $G\W_PGIY^%_C(ZK0X4Y^/5DN9HZ"ZB[3\Y];A8
MS?\ V*%O?6CZWY?0<ZBAN#ZN/8T.=D6/+&N))'H4/:VQOJLV[G>K_P"I%F]7
M^N_U>ZCTZRJ[I]M]KF$5LO96&M<1]/UVV/=7L_TE/Z53,+U'0^NX'6\0Y&&7
M--;MEM+P ^MT3M>UI<WW-^@]CO36DN(_Q98>0RC-SW@BC(]*NEYT%GI>KZEK
M/^#W7;-__&+MT$O_T?4,G$Q<NKT<JFO(JD.].UH>V1]%VUX<U5?V!T+_ ,K<
M3_MBO_R"OI)*:V+T[I^&YSL/%IQG/ #S56UA('&[TVMW*&/TCI.+:+L;"QZ+
M6SMLKJ8QPGZ4/8T.]RN))*4JC.D]+KR1EUX=#,D$N%[:F"S<X$/=ZH;OW/W.
MW*VDDII6=$Z-;8ZVW QK++#N>]U+"YQ/YSG.9N<Y1_8'0O\ RMQ/^V*__(*^
MDDI%?C8V32:,BIEU+HW56-#F':=S98^6^US55_8'0O\ RMQ/^V*__(*^DDIK
MLZ?@5XSL2O&J9BOD/H:QHK=N^GNJ V.W*EGU-HQV=)Z56S&MR]P J:&MJK_[
M4Y.RL-;^=L9_PUK%JH;?1]9^W;ZVUN_C=ME_I;OSMF[U=G_7$S(+@=:%>KOP
M_I4R8362)H2-^D'Y>/\ 0XN+]%A@X6/@XS,7';MKK'?DG\Y[_P"4Y'221AP\
M(X*X:]-;<*V?%QRX[X[/%Q?-Q?I6@9@X3+?79CU-NDGU QH=)^D=\;O=*9F!
M@UY+LNO&J9E6?3O:QHL=,?2M WN^BU6$DH\-'AK?7A[JGQV..]M.+LPMJJNK
M=5<QME;Q#F/ <TC^4URH-^K7U=:_U&],Q [F?19_Y%:22<M6    $ : !.DD
MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
M24M/N84-(VLX&.)MYQS.[#F_ >+GWTOOC\W9JM54L[PNJ*-I8J0 /3.F5:6=
M=R>FL]#%,NS!DIT5AK[8]&]YXS?7BWV*Q0&:H<=U)*YU1P0IB-^25R$11M)T
MNV?,SNT4E5^[V&RA]Z*V6Y&)AI(^8G7O2,._<D[,,/1IZ2BI9JZMK)HZ>AH:
M=#)-//*P2.*)!K9G8@ #GT-QS!!!4<3,W11S9IK4P<4<0[J*VP2>LBQQD(U/
M)BVL!<.4_%'(MM$O$+*U+A>+; N$EZMD0+&, =]44X):+G9<8_68+(AWD<8J
M>1#?HFGK<FWLQ4N?,OQXMU],I(2KA39U]-O%E]<N\G.,+7F++]QAN]DO5-'6
M6JYTS;T4\$JAD=3VP>?6.?D<5OCM!]F4G9F9C@J@ECT :<&Z:JB,,\>4;5OQ
M-M&]3(P_*#R."GUC?/%Z;LMYJG!"5V<+DT((PQ6.&FB)!Y^Z4^CQ&_46;[.A
MY&59(T+)1V6]RU# 8A5-.L8)Z,6<#DT?#2UU'O\ 7B.OS04/>TRMC3T[8'_-
M==]@?4J/7>BMO424N7+8R2YFNR:BD1UK3Q-LZV7#5ZU<6Z,:*T6FDCH+;;H4
MIZ&CA&ZD<:#!5 ["R.H='!5T88@@ZB"#TZ5$-' 4ROF O6Y<D .[%B<9J3'I
MB8]S[ KT'DS<,+Q4]X)*O*$CGU'?U%(/:DF1!T;PYN1<OBLWN#H?;O[H\CBY
M.4(ADS%0I'(=A9*%2P'I;PY M&9(3;K[;E=\L9OI44UEOF8<V. DB8X=9$QW
M6'0P5A_(,]VKJH*F1EL69Z0,]LN:+ZJ"4CN7PUM$^#KVUP8]EMG%G/-N,7#F
MPU J<L6VI35?:Z%L4FW&VTD#C'$C"1P ,55L?P'BY]]+[X_-V:QV?X*[Y4RS
M44]YSS7[(XZ2"0214V]_J54B! NW=WVV+Z,U54S1TU-3(TM142L$2-$!9F9F
MP   Q).S1;3E^J=.%V3ZEQEN%<5%SJUQ1[G*IP)4C%8 =B$MJ+ZO1+,0JJ,6
M8Z@ .<G2AX[Y]MI6LJXBW#.R5*8-3T\@P-UD1MDDRDB$$=S&=_:XP[!7<9<A
MVLC)E[F,N>K52IBEJKI3KKE1>]IZAC[Y@,$D[K4K]SCS'8>13<)<ZUX3(.:*
MS#+-RG;!+/<ZAO\ "9SJ6GJG//J20XZ@[8>CQ6^.T'V92=FL/#ZRQ.4N,@GS
M'<%7%*"U1L/A53(=@[GN(P>^<J!I06JWPBGH+9314E%3KLCAA0)&H])0!R."
MGUC?/%Z;LEKL%@M\MVOU]JHZ&RVJ ;TE14RG!$4#8.=CL506.H:9.R DJU-7
M9:/>O%:FR>OJ&:>KD':,KMN^QP]'B-^HLWV=#Z))U ;3IF#C3?:1Z7_=5,MI
MR1#*N#/;4D$M16;I&(6>555#SJF]L8<B\YHNS[M#9J9IY$'?2,-4<2;>ZD<A
M1VSI=LQWB3K+G>ZIZJK(.*J6U+&OL8U 1>T/0MV5\OQ"2X5[8R3N"8J:!2.L
MJ)B-BH#Z9."C6=*#+-DC/44H+U=8X'6U50^'6SRD;6<C\0P U =CN%@D*0W.
M+]ZL%>P_P*R,'JR3MW7Q*/[$GM:5UGN]');KM;)6@N%!*,'BD7F[8.U2-1&L
M<BANMKJ6HKG;)XZJWU:;8YHCO(WI8ZB.<8C2V9EIE6&KD!I[S0 XFFK(L!+'
MKYL>Z4\ZD'T;E\5F]P=#[=_='T:>FI:>6KJZR6.GHJ*!3)-//*P2.*)!K9W8
M@*!M.EBRS=U09HNLLM[S8(R&6.NK=TF -SB"-4BQV$J2-O)K\KYQL5'F.P7)
M-RLM=;&)(VPV,.=67:K*0RG6"#I57W@C<3F2T8M(V1KM,J7" ;=VDK7P2=1S
M+-NM[-CI46#,MGK<NWVD.%39KG ]+4IAS]7( 6'LEQ!YCV*CM=NI)[E=+C((
M;?:Z.)YZFHD8X!(H8PSN?2&E#F_CS3_R^U1E)[?PTCD#3U/JE-UFC)")TP1D
MD[)&&M#3T5%314='1Q)!24D"+'%%%& J(B* %50   , /P+B!F2TV>Q26K,.
M9+I<[7)+=DCD:GJJJ26(NG5'=)5AB,=6GT+E[RRG@M/H7+WEE/!:?0N7O+*>
M"T^A<O>64\%I]"Y>\LIX+3Z%R]Y93P6GT+E[RRG@M/H7+WEE/!:?0N7O+*>"
MT^A<O>64\%I]"Y>\LIX+0 V;+R@G L;RN [9PAT@FXC9TM.6;0&QJ:*QB2X5
M[J#WJRSQPPQ[P]5NOAT:092R%94M-LC;KJR=F,M565! #U%5.W=2R-AK)V#4
MH"@#T:7AUPDMUN@RW>T,F>;Y5W):.HGB5L$MT*;C$))AO2MZI<$&HMI@+)EX
M ;!_.4\#I]"Y>\LIX+3Z%R]Y93P6GT+E[RRG@M+9<.-%':H,C67"MJ+10UPJ
MY+I41L##2R@(NY#CW4G.P&YL8D)%$BQ11*$CC0!555&   U  =AGI*N".JI:
MJ-H:FFF4/')&X*NCHP(96!P(.HC2KO?"7, X?UE2S2296K(6J[/OL<3U&ZRS
M4PVG=4N@]2BC22.E@RO=8U;=2H@NKQAQZ[=FID(]+3Z%R]Y93P6GT+E[RRG@
MM&1['EYD<8,IO*:P?_2TCREQOHJ*2[Y9,=+8,RTE>M:]PH OO8JL%4K-#AN%
MM>^-UN^WO1S[G?*MJLT^7[_4TDMLFJ;FL$K+#0T\#[\9C;=[N-N?9I]"Y>\L
MIX+3Z%R]Y93P6GT+E[RRG@M/H7+WEE/!:?0N7O+*>"T^A<O>64\%I]"Y>\LI
MX+3Z%R]Y93P6GT+E[RRG@M/H7+WEE/!:?0N7O+*>"T^A,O>64\%I%_O/-F7\
MHVH-A4-;S-=*QE__ %HR4\2GMLQ](Z26+)%M9*BO9);]F&L837"XS("%>HFP
M&I02%10J*.]48G'D<-(>'M%;ZQ\L5ESFNXKZP4@5*J&!(MS%&WL2AQZ-/H7+
MWEE/!:?0N7O+*>"T^A<O>64\%I]"Y>\LIX+3Z%R]Y93P6GT+E[RRG@M/H7+W
MEE/!:?0N7O+*>"T^A<O>64\%I]"Y>\LIX+2..]7'*V6*,X&:K>LGKI%&.L+#
M#"@8X=,@';T-ZI'ES9GRHA:"JSG<8T5XHW[^*B@7%:=&V-@2[>J<C5R,Y9YR
MC:[-49=O45N2@FJ[FM/,334<<,F]$8VPP=3AKUZ?0N7O+*>"T"2V_+5&I(!E
MENY90#M.$=.YU>EI27SC%F*'.LM(XDBR?;8W@M+.IQ7X5+)[]4+[#!%/J@PU
M:0TM+#'34U-&L5/3Q*$2-$&ZJJJX   8 #D4G#RV3AK;E\I69@9#B)*YUQAA
M)!V0HV\1ZYAZWT*2W6ZDDK[C<)DIZ"AA&])--(<$11TD_DV[- M2L=5FR\*D
MN8KDNL!@,5IHCS1Q8X#UQQ8[=79%ENU.]NOM.G5T68Z+!*E%YDDQ!65,=>ZX
M.',1H_\ ([O:+_2[QZII'DHI]WFWD99$Q])]/HVU>4%_0T^C;5Y07]#3Z-M7
ME!?T-)'N-!;Y,J7U.JOU/%7J[QR1@F&IC3=&+*>Y8<ZGM#T:R", R3021Q@G
M ;S*0->A!LF7N^8_3*<Y)_TM/H7+WEE/!:1Q7&;*V7Z=C[Y5S7&:I*#M1P4Y
MWO\ J&E-FR[5CY\S_3J?@E\K(5BI+>S#!C04F+A&YNM=F?#85!([!_*,^Y1M
MF:J$ B)*^G61XB=9,,NJ2,]M&!TGJ^'&<KKDRH;>:.TW$"[4&\3B%5G:.H1?
M3D;25[5:K/GJCB!;K[/7K#,PZ/@]:(#CV@QT;_</"K-EK13@9C:JB>/\4E.L
MJ'TP<-#'6T5712+WT=33RPL/3$BJ=,&J8U(VJ6 /Y#IA'*)3LP3NO^&.B163
M*U[O,DAPC6AMM748GTXXF']^B+0\+;C9X'P)K;_)#:XP.DK,_6G\49T@J^*7
M$.*B@#*TUBRQ"7D9?5(U=5J IYL5@/IZ&/(64:6VW"6,1UN89\:JYU  P/6U
M<Q:0@^M!"]K_ ,3W;,T^[+5Q**>ST9_SZV;%88_2Q[IO8@Z55?7U#5=?7S25
M-=5N<6EFE8O(Y]-B="S' #63I'GS--)U>9KI"19K=*.ZMU)(-K#FFF'?>M7N
M=N]_\&ZNJIHJF/UDJ*X_(P.A>3+5JD=N^=J. D^F2F@-+8K=3$'$&*EB37LQ
M[E1H !@!L _\5?R&W3]9E_)CR4T3*<4GKV[FHEU;1'AU:_\ -T^A2\0\STF]
ME^WR;^6;?*.YK:F,X?"7!VQ1,.X&QFU[%U_V)5=10S"/,=\)M^7E]4DKK[Y/
MAB-4*8MZ>Z.?0#$L>=V.)).LDGG).LZ,U:LD&3K+(K7^L7%3.^IEHHF]<XUN
M1WJ]MAI345' E+24<20TM-$H5(XXP%1%4:@ !@!_8DSNP5%!+,3@ !M).E=<
M*:8OE^S;UNRXGJ6A1O?:C#5KF<8@^M"Z4F6;&O5O*.MN=R9=Z.BI0<'G?I/,
MB^J;5TZ6[+5@IA36ZW1[JXZWED.N2:5MK.[8LQZ>U_8F,KVRH,>8,Y))3[R'
M!Z>@754RZM8+@]6OID\VENL5DHVK;I<YEIK=11ZMYSTG8JJ!BQ.H $Z+:X72
MMO=>5J,Q7@+@:BHPP"ICK$<8.Z@/-K.LG^Q.KN-?.E+0T$+U%94N<%CBC4L[
M$]  QTN^:JA9!!62"GLE%@6:*CC.[3Q*HVLV.\0-K-I_NG,=*/\ >EZA $+C
M$VVE? BG7HD;493TX*-0U_V)T?#FV5 6JO2K6YE=6_PZ%&][A8\W7.N)!]2I
MZ=*/B9FJD_=XFZS)MKF7OS_[^13S?Z0/M_6_V*W/.V;:NNSE=KC6&J6DN#HM
D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
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M/'(4,C,97T8&1H\>C1T[=I@\'X\V;=F"F7-F8]28^S"4]:QR#1Z:CG&3)AI
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M#VGZC!D$W$@,26<Y*?P):<.1.&2XD9\A%'RY 2*_CT!BUL/(.N&Q? T.+4K
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MF#]_/LKY$A6HO/[ZZZBNKL;<N7-15%1DKLDSZ X=%TPLO?GFFXCBFS"!"I]
M5R1QB HVE!E/I[ ,<9A(G,)C&@N>8@K9/=:;*RDIF<K!MR[!)#\_O^,MWUGI
M=_,M.IPN3B2M@\2T5*305$^F0L53R>.9KQC&$<-\O/36"M.A*)-12JZR*$Z=
MBP52H0WI=%*UX_G77L5=?&,G,:YXQI5(D$MA&5/2AK!L!+OX1)JM8W'@P(&.
ML#(70_,I2T' F$CK(8%EBTNC,J53&,B)=(T2&5?B8"HU\YZ0DDK!4QVR7H,
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MS"C;?;P?] OU6[/SI!#FJW(\2D%Z B3VT8JJ2N33!%0^!ZLQ4P<[BA-DY5?
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M7AQ D1(QW\%KH=P5F)@.,=:3CI$"DSD/T9((^N4,Z"Q<Y+%3O72'U4:6PY'
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MW6[MM4HP8]H*WYF/"R8:Z^>Y]I.=-7NN60PI8C$=ECRHS-UDM8VU1BR'HZ[
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MTM5H#D& 5H0^6>$]LA'%CPS'P>RKT#+U+'AR?X&FW'[87? _./+10BHUW;.
MRX"8Z; EZV@ P_QWK!+E2JQ[6LR']F:T__@&]LR^%8<+KT5YX8VH*K@!;7F7
M(C#^5\"X\^CZ7(5-^3>B_.OY#%#,^+13/0,K(D5MY/*G8"*],!M!\RCK6& B
M4 AGF8C4P?K8XD6X8\#=9CI#$D$HGHIOON3'<+*X]:UAR7,$K12Y\]$$E[3A
MF1@U=AS&9V5A2E8.QHZ;0)!67TBLZ71-'S'"R)K55Z.SU MUP&HOY-=7.!N
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M#<WD,!@BLZ3/-#FCJ0],^NBTDD## 0R!!<%$4]>-7>* B?-+(*(S7>VC,Y.
6_Q]L!4#4?=TOGP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481604615536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M"  6@099EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ %H$&60=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  6
M@099%-#?/N\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  6@099F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !:!!EF;U][E
M4 0  'X0   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  6@099GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"  #L$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20240806.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20240806.htm">exel-20240806.htm</File>
    <File>exel-20240806.xsd</File>
    <File>exel-20240806_lab.xml</File>
    <File>exel-20240806_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20240806_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20240806.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20240806",
   "dts": {
    "inline": {
     "local": [
      "exel-20240806.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20240806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20240806_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20240806_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20240806.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20240806.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0000939767-24-000116-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-24-000116-xbrl.zip
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M8+T\@D4,#H#*?>:IS_:YVD0P"J"0F!*$Q?!?>4N'\ QW@PX5!YRA70K1NWT
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MIFF^!XF3F>6'$Q0@$Y!]V@$J<7>OB[:E'![U^8<*_UP#P9\J;+T#J&'$9S(
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ML#JG/^0!8L_#[U9LO0P+&WY]2]8E&_QJ6>82-;J:7RLX,?1?$#=E>KXE=,S
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M<$8_6[!>FC\K7OB?%4-G#]R/RC$WO-^/BK:GA]:/"NCMGZ(UD.YN.X[8V>N
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M'%8+\$8@W5%X'F<4N!]5X9VNKN/E0;NH\%K+&DD8>6NB3J+U K$H\\!C%LA
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M!DF&I$/R(,602L@3R O(&\A;R"?(.&0.L@J%0:FAS%!.J !4'*H /0(U@%I
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MT C0J-/8TN!I8FGR:!IH/M LTS+1BM'JT[K0AM'>HBVC[:"=HJ.@XZ<[0N=
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M.P,^L$J% O7H0N0O&D(=>SK>'0( ,$SMP!@#R$-.O6%) A,NUBWM?MF5JSS
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M.LH[*121TT)YJ _4JDN'=5>?(F--K8]_:\C^&5)F3HL%1?<('!DR?.SL)?6
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M.^QSKV7O.7O?@-E6,U=ZX96%VV$S,TOK[H*4P0XAYLB$F3#^XH5O.KIVN5N
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MD>X7H5D!%FLH\+(GB;>CJZ/6ZL$'61.Z;_EM3 M/"=&Z9Q>-9-+;VII#%!$
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M7YIU2@C2@Y\8JFT-XG'_4F65A?BS,IQ_6$4UE4 QN7P+[E^!G#L.F+:?4TD
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MVN<IY:\BSU_4"6 *8RI\:/(8_I*' KM]@U&#PX5\HID?$WI,&5OP 6$S#Y]
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MV(_NFF*BFKM'.6Z(<%_S&3KSH9![+[ATP(3H(W[Z(1O?,FCE4J:FJL'P=P3
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M0!;?%N.]RS,V'S1G6ZZMX]>0QVM-:XI+*X81JO@%[?7[M^P?IE80:ZFH&?.
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MR FF@#LKUTH4KWKV]?J7\/1D&.[=>,WKG=>,XFR?5_+4U]6)5)(CF4V*JHG
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M3;/VPCLPY"KAWNF25 3@_SLD)7>CHW&\#C.7:;T]@78S%$F2WY79A26BV5@
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M<,&/AC1V>$14S6$<P$N_3#_GW2 =[D44=* A%WA;E"H>_9.16F.K4!>JI'<
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M[XIP=B>3/P VP^)\A,[0?I#V:6B_145M3<:E%/L\@=[J;?)3][M)1S7<>CX
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MSO<]>V7-38[X 6STRT4EI_)3\[UBFP 55H?26IX:>=*>E."6)$J6ZN&Z!'V
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M[A83O9A?5)4>VD^2H,P%QS5,RE-<TW''NI7#A8W/B*4M#5?0KCGF.:+^DO;
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MWPU:8<L\U\CJS?L3_X-,, 4;P:;74>9W5%R7?7TOKN8UU5/63=J;9W56  !
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MT^.5\ L!XI#_U_6=;9_66#BHJZAI*\)Y32<5N>0LH.(Z6L_/4="Q(VU0@_[
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MC@Q(:01PL]W2\0- 71/<$D;![BQ%M^FRRS1^(-WY)V8O8F9A=6V"I86.-BB
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MW+YT#R[F9A70@;\_F(%=^P*D@0<^A4K2.;''0%CB(YAWXV*FJ"ED53D"@Z/
M$*9@R 5&:+EZ%1,1*2MY=FNNKINL8#27>@X?^5#5W:#2&UCPK9;8][AT_H(
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M?@X\>PJ_QM'$^?7_ U!+ 0(4 Q0    ( !:!!EGV^UN_Y1   +9M   1
M          "  0    !E>&5L+3(P,C0P.# V+FAT;5!+ 0(4 Q0    ( !:!
M!EDKM;DL; (  'T'   1              "  101  !E>&5L+3(P,C0P.# V
M+GAS9%!+ 0(4 Q0    ( !:!!EG5W1!EJJ<  (?8   4              "
M :\3  !E>&5L+3(P,C0P.# V7V<Q+FIP9U!+ 0(4 Q0    ( !:!!EF*#/\S
M, H  'U5   5              "  8N[  !E>&5L+3(P,C0P.# V7VQA8BYX
M;6Q02P$"% ,4    "  6@099+MV>&Z@&  #J,   %0              @ 'N
MQ0  97AE;"TR,#(T,#@P-E]P<F4N>&UL4$L! A0#%     @ %H$&6:*8__:
M-@  ATH" !H              ( !R<P  &5X96PR,#(T,#8S,&5X:&EB:70Y
<.3$N:'1M4$L%!@     &  8 C@$  ($# 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>exel-20240806_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20240806.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2024-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $0.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
